Shares of Epizyme Inc (NASDAQ:EPZM) rose 7.5% during mid-day trading on Tuesday . The company traded as high as $16.40 and last traded at $16.40. Approximately 666,700 shares changed hands during trading, an increase of 23% from the average daily volume of 543,436 shares. The stock had previously closed at $15.25.

EPZM has been the topic of a number of recent research reports. Cann reissued a “buy” rating and set a $26.00 price objective on shares of Epizyme in a report on Tuesday, December 12th. Royal Bank of Canada cut Epizyme from an “outperform” rating to a “sector perform” rating and dropped their price objective for the stock from $20.00 to $16.00 in a report on Thursday, November 2nd. BidaskClub cut Epizyme from a “sell” rating to a “strong sell” rating in a report on Thursday, December 21st. HC Wainwright reissued a “buy” rating and set a $25.00 price objective on shares of Epizyme in a report on Thursday, November 2nd. Finally, Zacks Investment Research cut Epizyme from a “hold” rating to a “sell” rating in a report on Wednesday, January 3rd. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and ten have assigned a buy rating to the company. Epizyme has a consensus rating of “Buy” and a consensus target price of $22.40.

The stock has a market cap of $1,140.00, a price-to-earnings ratio of -7.25 and a beta of 2.00.

Epizyme (NASDAQ:EPZM) last released its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.63) earnings per share for the quarter, beating the consensus estimate of ($0.65) by $0.02. sell-side analysts predict that Epizyme Inc will post -2.23 earnings per share for the current fiscal year.

Several large investors have recently added to or reduced their stakes in the business. NEA Management Company LLC raised its holdings in shares of Epizyme by 3.2% in the 3rd quarter. NEA Management Company LLC now owns 6,460,851 shares of the biopharmaceutical company’s stock valued at $123,079,000 after acquiring an additional 200,000 shares in the last quarter. Palo Alto Investors LLC raised its holdings in shares of Epizyme by 18.9% during the 2nd quarter. Palo Alto Investors LLC now owns 5,698,296 shares of the biopharmaceutical company’s stock valued at $86,044,000 after buying an additional 907,245 shares in the last quarter. Vanguard Group Inc. raised its holdings in shares of Epizyme by 6.2% during the 2nd quarter. Vanguard Group Inc. now owns 3,419,844 shares of the biopharmaceutical company’s stock valued at $51,640,000 after buying an additional 200,982 shares in the last quarter. State Street Corp raised its holdings in shares of Epizyme by 59.6% during the 2nd quarter. State Street Corp now owns 1,764,450 shares of the biopharmaceutical company’s stock valued at $26,644,000 after buying an additional 658,727 shares in the last quarter. Finally, Point72 Asset Management L.P. purchased a new position in shares of Epizyme during the 3rd quarter valued at about $17,591,000. 85.29% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: “Epizyme (EPZM) Stock Price Up 7.5%” was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark law. The correct version of this news story can be viewed at https://www.thecerbatgem.com/2018/01/23/epizyme-epzm-stock-price-up-7-5.html.

About Epizyme

Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs).

Receive News & Ratings for Epizyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme and related companies with MarketBeat.com's FREE daily email newsletter.